Martine E. B.
- Country
- France
- Department
- Hématologie
Research Overview
- Randomized Precision Medicine Trial of Venetoclax Combination Therapy in Relapsed/Refractory T‑Cell Acute Lymphoblastic Leukemia
- Evaluation of Minimal Residual Disease-Based Strategy with Teclistamab Post-Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
- Phase 3 Evaluation of Daratumumab with Bortezomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide, and Dexamethasone in Untreated Multiple Myeloma
Data & Insights
Has run more than one trial at 82 of 174 partner sites.
Specializations
Chronic Myelogenous Leukemia (CML)
The investigator specializes in treating chronic myelogenous leukemia, focusing on various disease stages including chronic phase and accelerated phase.
- Novel therapeutic combinations
- Treatment optimization strategies
- Disease progression management
Particular emphasis is placed on developing innovative treatment approaches using targeted therapies like ponatinib and established treatments like imatinib.
Multiple Myeloma
Extensive work in multiple myeloma treatment with focus on newly diagnosed patients and maintenance therapy approaches.
- Minimal residual disease monitoring
- Novel therapeutic combinations
- Stem cell transplantation protocols
Special interest in quadruplet therapy regimens and the integration of new agents like daratumumab and elranatamab in treatment protocols.
Acute Lymphoblastic Leukemia
Dedicated research in acute lymphoblastic leukemia treatment, particularly focusing on young adult populations.
- Age-specific treatment protocols
- Treatment optimization
- Clinical outcomes assessment
Specialized focus on developing targeted therapeutic approaches for ALL patients between 18-59 years of age.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.